ClinicalTrials.gg
RecruitingNCT07013903HydroCoVital AUpdated Aug 28, 2025

Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

An interventional study of Standard rehabilitation plus cold water hydrotherapy and Standard rehabilitation only in Post-COVID / Long-COVID, POST-Covid 19 and Post COVID Syndrome, sponsored by Schön Klinik Berchtesgadener Land. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Planned enrollment
23rd of 28
50 · median 108
Started
2025
with 6 others
No phase
20 of 41
7 open now
Primary completion
2027-01
later than 8 of 16 live
Registered
35th of 41
by date
Lead sponsor
3 of 41
Schön Klinik Berchtesgadener Land

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 23rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 35th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.

Read the detailed description

Patients recovering from Post-COVID Syndrome often experience persistent fatigue, autonomic dysregulation, microcirculatory disturbances, and low-grade inflammation, all of which may hinder their return to full function. Kneipp hydrotherapy-using cold water applications-can address these pathophysiological changes through several mechanisms:

Autonomic regulation: Cold stimuli trigger parasympathetic activation and improve sympathovagal balance, helping to stabilize heart rate variability and reduce symptoms of dysautonomia often seen in Post-COVID.

Enhanced microcirculation: Repeated vasoconstriction and reactive vasodilation promote endothelial function and tissue perfusion, which may alleviate muscle aches, dizziness, and fatigue by improving oxygen and nutrient delivery.

Anti-inflammatory effects: Hydrothermal stimuli have been shown to modulate cytokine profiles, increasing anti-inflammatory mediators and potentially dampening the persistent, low-grade inflammation implicated in Post-COVID pathophysiology.

Musculoskeletal recovery: Thermo-mechanical stimulation relaxes tense muscle fibers, reduces pain perception, and supports gradual increases in physical capacity, all of which are important for overcoming Post-COVID deconditioning.

Taken together, these effects suggest that adjunctive cold water hydrotherapy could accelerate functional recovery, reduce symptom burden, and enhance quality of life in Post-COVID rehabilitation.

Baseline Assessments:

At baseline, demographic data including sex, age, height, and weight will be collected. Participants will report their current main Post-COVID symptoms, which will be categorized into symptom clusters: Fatigue (A), Cognitive (B), and Somatic (C). Smoking history will be assessed, including smoking status (current, former, or never), number of cigarettes per day, years of smoking, and pack-years.

The time (in months) since the COVID-19 infection that led to Post-COVID syndrome will be documented, along with the number of COVID-19 vaccinations received at the time of infection. Employment status will be recorded, distinguishing between full-time or part-time employment, COVID-related work disability, retirement, unemployment, or disability pension.

Comorbidities will be documented across the following categories: cardiovascular, pulmonary, cerebrovascular, metabolic, musculoskeletal, psychiatric, and other conditions. The severity of the acute COVID-19 illness will be assessed using the WHO Clinical Progression Scale, including information on any hospital admission and length of stay (in days).

Pulmonary function testing at baseline (V1) will include FEV₁, FVC, FEV₁/FVC ratio, and total lung capacity (TLC), all expressed as percent predicted. Autonomic function will be evaluated using the Schellong test. Vascular status will be assessed by four-limb blood pressure measurement. Additionally, self-reported work ability and the number of Post-COVID-related sick leave days within the past 12 weeks will be recorded.

03

Conditions studied

  • Post-COVID / Long-COVID
  • POST-Covid 19
  • Post COVID Syndrome
  • Post-COVID Condition

Keywords

  • rehabilitation
  • therapy
  • Post-COVID
  • Long COVID
  • intervention
  • hydrotherapy
  • Kneipp
  • balneotherapy
  • Post-COVID condition
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)
  • Barthel-Index >80
  • Referred to the reference center for Post-COVID rehabilitation
  • Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability
  • Written

Exclusion criteria

Exclusion Criteria:

  • Existing for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)
  • Prior regular practice of Kneipp applications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Post-COVID Rehabilitation with hydrotherapy

    Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period

    Other: Standard rehabilitation plus cold water hydrotherapy

  • Active comparator
    Post-COVID Rehabilitation without hydrotherapy

    3-week inpatient multimodal inpatient rehabilitation program without hydrotherapy

    Other: Standard rehabilitation only

Interventions

  • OtherStandard rehabilitation plus cold water hydrotherapy

    Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period

  • OtherStandard rehabilitation only

    same rehabilitation program than the experimental group but without hydrotherapy

06

What researchers measure

Primary outcomes

  1. Health-related quality of life by Short Form-12 Health Survey (SF-12)

    Change in the Short Form-12 physical and mental component summary scores

    Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)

Secondary outcomes

  1. Fatigue severity by Fatigue Severity Scale

    Change in Fatigue Severity Scale score

    Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)

  2. Sleep quality by Pittsburgh Sleep Quality Index

    Change in Pittsburgh Sleep Quality Index score

    Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)

  3. Health status by EuroQol-5 Dimensions-5 Levels

    Change in EuroQol-5 Dimensions-5 Levels questionnaire score

    Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)

  4. Autonomic function (heart rate variability by photoplethysmography)

    Change in heart rate variability (root mean square of successive differences) measured by Kyto 2935 via photoplethysmography

    Time frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)

  5. Resting blood pressure (systolic and diastolic)

    Change in morning resting systolic and diastolic blood pressure

    Time frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)

  6. Post-COVID work-absence days

    Number of days of work absence due to Post-COVID-19 symptoms during the past 12-weeks

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  7. Long-term quality of life by Short Form-12

    Change in Short Form-12 scores at follow-up

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  8. Long-term fatigue by Fatigue Severity Scale

    Change in Fatigue Severity Scale score at follow-up

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  9. Adherence to hydrotherapy

    Proportion of prescribed hydrotherapy applications in the intervention group performed, as recorded in diary or app. Short-term Adherence: During the 3-week intervention phase, patients are considered "adherent" if they perform at least one hydrotherapy session per day on at least 75% of study days. We will compare health improvements between high-adherence and low-adherence participants. Long-term Adherence and Effects: Over the 3- and 6-month follow-up, "adherent" patients are those who continue self-administered hydrotherapy at least four times per week on at least 75% of follow-up weeks. We will assess whether these patients sustain greater gains in quality of life.

    Time frame: During the 3-week intervention phase (up to Visit 2) and over the 6-month follow-up period (to Visit 4)

  10. Adverse events recording

    Number and severity of adverse events related to Kneipp hydrotherapy

    Time frame: From start of intervention (Visit 1) through end of study (Visit 4, 6-month follow-up)

  11. Long-term heart rate variability changes (HRV)

    Change in heart rate variability parameters (root mean square of successive differences) measured by photoplethysmography. At follow-up visits patients will measure HRV for 7 consecutive days

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  12. Post-exertional malaise severity

    Change in Post-Exertional Malaise score measured by the DePaul Symptom Questionnaire-Post-Exertional Malaise

    Time frame: From baseline (Visit 1) to 6-month (Visit 4) follow-up

  13. Daily well-being documentation

    Self-reported daily well-being recorded via digital diary on a scale from 0 to 100

    Time frame: Daily throughout the intervention and 6 months follow-up phase (Visit 1 to Visit 4)

07

Study locations

1 of 1 sites recruiting
  • Schön Klinik Berchtesgadener Land
    Schönau am Königssee, Bavaria 83471, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 17 months is close to that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 10, 2025
StartActual
Aug 21, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07013903
Lead sponsor
Schön Klinik Berchtesgadener Land
Collaborators
Bavarian Health and Food Safety Authority (LGL)
Responsible party
Prof. Dr. Andreas Rembert Koczulla (Professor, Schön Klinik Berchtesgadener Land) — Principal investigator
First posted
Jun 10, 2025
Start date
Aug 21, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Aug 28, 2025

Study contacts

Rainer Gloeckl, PhD
Contact
rgloeckl@schoen-klinik.de
+498652931630
Rembert Koczulla, MD
principal investigator · Schön Klinik Berchtesgadener Land

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion